Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Rocket Pharmaceuticals Inc is a biotechnology business based in the US. Rocket Pharmaceuticals shares (RCKT) are listed on the NASDAQ and all prices are listed in US Dollars. Rocket Pharmaceuticals employs 91 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$28.97|
|52-week range||$26.72 - $67.48|
|50-day moving average||$32.10|
|200-day moving average||$39.01|
|Wall St. target price||$69.78|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.79|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||3.76%|
|1 month (2021-09-22)||-10.67%|
|3 months (2021-07-22)||-40.84%|
|6 months (2021-04-22)||-34.90%|
|1 year (2020-10-22)||0.56%|
|2 years (2019-10-22)||105.17%|
|3 years (2018-10-22)||62.02%|
|5 years (2016-10-21)||273.81%|
|Gross profit TTM||$0|
|Return on assets TTM||-22.43%|
|Return on equity TTM||-43.57%|
|Market capitalisation||$1.8 billion|
TTM: trailing 12 months
There are currently 8.1 million Rocket Pharmaceuticals shares held short by investors – that's known as Rocket Pharmaceuticals's "short interest". This figure is 2.4% up from 7.9 million last month.
There are a few different ways that this level of interest in shorting Rocket Pharmaceuticals shares can be evaluated.
Rocket Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rocket Pharmaceuticals shares currently shorted divided by the average quantity of Rocket Pharmaceuticals shares traded daily (recently around 398498.57283465). Rocket Pharmaceuticals's SIR currently stands at 20.32. In other words for every 100,000 Rocket Pharmaceuticals shares traded daily on the market, roughly 20320 shares are currently held short.
However Rocket Pharmaceuticals's short interest can also be evaluated against the total number of Rocket Pharmaceuticals shares, or, against the total number of tradable Rocket Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rocket Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Rocket Pharmaceuticals shares in existence, roughly 130 shares are currently held short) or 0.1759% of the tradable shares (for every 100,000 tradable Rocket Pharmaceuticals shares, roughly 176 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Rocket Pharmaceuticals.
Find out more about how you can short Rocket Pharmaceuticals stock.
We're not expecting Rocket Pharmaceuticals to pay a dividend over the next 12 months.
Rocket Pharmaceuticals's shares were split on a 1:4 basis on 4 January 2018. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rocket Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Rocket Pharmaceuticals shares which in turn could have impacted Rocket Pharmaceuticals's share price.
Over the last 12 months, Rocket Pharmaceuticals's shares have ranged in value from as little as $26.7197 up to $67.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rocket Pharmaceuticals's is 1.5519. This would suggest that Rocket Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Rocket Pharmaceuticals, Inc. , together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.